Sustained-Release Corticosteroid Options

Sustained-release corticosteroid treatment has shown to be a promising strategy for macular edema due to retinovascular disease (i.e., diabetes and retinal vein occlusion) and for the treatment of noninfectious posterior uveitis. Clinicians now have the option of three sustained-release corticosteroid implants: Ozurdex (Allergan Inc., Irvine, CA) which releases dexamethasone and two devices that release fluocinolone acetonide, Retisert (Bausch & Lomb, Rochester, NY), and Iluvien (Alimera Science, Alpharetta, GA). Each has different physical characteristics and duration effect and has been approved for different indications. Herein we provide a summary of the current clinical knowledge regarding these implants.

[1]  M. Postorino,et al.  Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema , 2013, Ophthalmologica.

[2]  A. Loewenstein,et al.  Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  Bernd Junker,et al.  Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review , 2013, PloS one.

[4]  Q. Nguyen,et al.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. , 2013, Ophthalmology.

[5]  J. H. Park,et al.  Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[6]  H. Flynn,et al.  Intravitreal Corticosteroids in the Management of Diabetic Macular Edema , 2013, Current Ophthalmology Reports.

[7]  A. Vestri,et al.  Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema , 2013, Clinical ophthalmology.

[8]  Rishi P. Singh,et al.  Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. , 2012, American journal of ophthalmology.

[9]  P. Campochiaro,et al.  Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. , 2012, Ophthalmology.

[10]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[11]  T. Louis,et al.  Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. , 2011, Ophthalmology.

[12]  P. A. Pearson,et al.  Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. , 2011, Ophthalmology.

[13]  M. Blumenkranz,et al.  Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion , 2011, Clinical ophthalmology.

[14]  S. Whitcup,et al.  Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. , 2011, Investigative ophthalmology & visual science.

[15]  Frank G Holz,et al.  Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. , 2011, Ophthalmology.

[16]  Gabriel Coscas,et al.  Steroids and Macular Edema from Retinal Vein Occlusion , 2011, European journal of ophthalmology.

[17]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[18]  S. Whitcup,et al.  Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. , 2010, Investigative ophthalmology & visual science.

[19]  M. Zierhut,et al.  Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. , 2010, Ophthalmology.

[20]  C. Flaxel,et al.  Management of fluocinolone implant dissociation during implant exchange. , 2009, Archives of ophthalmology.

[21]  Glenn J. Jaffe,et al.  Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. , 2008, Archives of ophthalmology.

[22]  P. A. Pearson,et al.  Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. , 2006, Ophthalmology.

[23]  P. McCluskey,et al.  Outcome of intravitreal triamcinolone in uveitis. , 2005, Ophthalmology.

[24]  P. A. Pearson,et al.  Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. , 2004, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[25]  G. Jaffe,et al.  PHARMACOKINETICS OF THE FLUOCINOLONE/5‐FLUOROURACIL CODRUG IN THE GAS‐FILLED EYE , 2000, Retina.

[26]  R. Machemer,et al.  The clearance of intravitreal triamcinolone acetonide. , 1982, American journal of ophthalmology.

[27]  G. Jaffe,et al.  Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. , 2012, Ophthalmology.

[28]  J. Vander.  Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis , 2012 .

[29]  M. D. de Smet.  Corticosteroid intravitreal implants. , 2012, Developments in ophthalmology.

[30]  Cathy Frey,et al.  Investigative Ophthalmology and Visual Science , 2010 .